Abstract

A REVIEW ON ANALYTICAL METHOD DEVELOPMENT FOR SIMULTANEOUS ESTIMATION AND VALIDATION OF MONTELUKAST SODIUM AND BILASTINE

Krishna P. Vairagi* and Dr. Shuchi P. Desai

Abstract

Bilastine is a selective histamine H1 receptor antagonist. It binds to and prevents the activation of the H1 receptor, reduces the development of allergic symptoms due to the release of histamine from mast cells. So, it acts as antiallergenic and acts to reduce allergic symptoms such as nasal congestion and urticaria. Montelukast Sodium is a leukotriene receptor antagonist that binds with CysLT type 1 receptor, which consequently assists in inhibiting any physiological actions of CysLTs like LTC4, LTD4, and LTE4 at the receptor that may facilitate asthma or allergic rhinitis. And hence it’s mainly used to control and prevent symptoms caused by asthma (such as wheezing and shortness of breath) and in allergic rhinitis. Both drugs in combination are used in treatment of allergic rhinitis and mild to moderate asthma. In this review, there is involvement of analytical methods on Bilastine and Montelukast Sodium. However, there are no any methods available for combination of Bilastine and Montelukast Sodium. There are UV, HPLC, HPTLC and UPLC method on Bilastine and Montelukast Sodim either individually or along with other drugs. This review can be used for further analytical method development.

Keywords: Allergic rhinitis, Bilastine, Montelukast sodium, RP-HPLC, HPTLC.